Carrow Wells

GlaxoSmithKline

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (11)

Christopher R. M. Asquith

University of North Carolina

UNITED STATES

View details

David H. Drewry

University of North Carolina at Chapel Hill

UNITED STATES

View details

John Scott

Lab Head, Neurometabolism

Monash Institute of Pharmaceutical Sciences

AUSTRALIA

View details

Daniel Frigo

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Michael Major

Professor

Washington University in St. Louis

UNITED STATES

View details

Opher Gileadi

Head, Protein Sciences

Karolinska Institutet

SWEDEN

View details

Tigist Tamir

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES

View details

Hassan A Ali

University of Miami

UNITED STATES

View details

Daniel Ebner

University of Oxford

UNITED KINGDOM

View details

Alison Axtman

Research Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES

View details

Jon Oakhill

Australian Catholic University

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carrow Wells

Research Interests

Explore related searches

Contact this professor

Articles (10)

SGC-CAMKK2-1: A Chemical Probe for CAMKK2

Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review.

Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification

A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation.

Towards a RIOK2 chemical probe: cellular potency improvement of a selective 2-(acylamino)pyridine series.

A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.

PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.

Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases.

Quantifying CDK inhibitor selectivity in live cells.

Collaborators (11)

Christopher R. M. Asquith

David H. Drewry

John Scott

Daniel Frigo

Michael Major

Opher Gileadi

Tigist Tamir

Hassan A Ali

Daniel Ebner

Alison Axtman

Jon Oakhill

Make your next move.